We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Tufts Center for the Study of Drug Development Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates
News

Tufts Center for the Study of Drug Development Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates

Tufts Center for the Study of Drug Development Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates
News

Tufts Center for the Study of Drug Development Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tufts Center for the Study of Drug Development Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CRAs are based in the field and they are responsible for overseeing and closely monitoring clinical studies conducted by research centers.

"Over the past 15 years, demands on study monitors have intensified as clinical trial volume and complexity have increased. Yet, drug development managers haven't had benchmarked global metrics to assess their CRA field force capacity and utilization," said Ken Getz, Tufts CSDD senior research fellow and assistant professor at Tufts University, who conducted the study.

According to Tufts CSDD, CRAs worldwide spent approximately 20% of their time traveling and devoted 41% of their time at clinical trial sites. Getz noted that prior to the study the research-based drug industry widely believed that CRAs spent 60% of their time on-site.

In addition, the study found that CRA workload and time allocation varies widely by geographic region with U.S.-based study monitors spending more time traveling and on-site than their counterparts elsewhere. European study monitors spend relatively more time performing off-site monitoring and administrative tasks.

According to Tufts CSDD, there are 20,000 - 23,000 CRAs supporting clinical research studies worldwide.

"CRAs play an integral role in the drug development process as they are the people who ensure the safety of trial participants, the quality of clinical data, and the compliance by investigative site staff with the study protocol," said Getz. "Knowing how much time CRAs spend on specific tasks gives managers and regulators a way to refine practices and policies aimed at enhancing CRA effectiveness and efficiency."

The Tufts CSDD study, reported in the January/February Tufts CSDD Impact Report, released today, also found that:

•    For Phase I studies, CRAs on average conduct 3.8 investigative site visits each month.

•    For Phase II-III studies, CRAs on average conduct 7.9 investigative site visits each month.

•    CRAs overall have an average of 6.3 years on the job and expect to remain in their position for another 3 years, with both metrics varying widely by region.

Advertisement